The six important active constituents—β‐sitosterol, diosgenin, formononetin, kaempferol, luteolin and quercetin—were chosen for molecular docking verification with the key targets AKT1, CAV1, DPP4, IL6, INSR, MAPK8, MMP9, PPARG and SLC2A4, which are considered potential targets in the treatment of diabetes. This evidence concerns the gene CAV1 and diabetes mellitus.